Maze Therapeutics Inc MAZE

$26.43 -0.22 (-0.83%)

Valuation

Market cap
1,480,381,000
Revenue TTM
$0
Net income TTM
$-131,120,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.11

Trading

Volume
633,000
Avg volume
571,708
Day's range
$26.36 – $27.49
Shares out
55,549,000
Stochastic %K
36%
Beta
2.16
Analysts
Strong Sell
Price target
$61.50

Price

Company profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibit...

Show more

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 850 5070
Website
https://www.mazetx.com
Address
171 Oyster Point Blvd, Suite 300, South San Francisco, United States

Latest news

Stocktwits

NickyProfits Sep 28, 10:14 PM
$BIIB $MAZE $MLTX hmm
0 replies
stockwuzet Sep 24, 1:29 PM
$MAZE
0 replies
StocktwitsNews Sep 22, 5:01 PM
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder $VRTX $MAZE https://stocktwits.com/news/equity/markets/twin-moves-vrtx-rises-on-kidney-disease-trial-results-maze-rallies-harder/cZMPusmRB7c
1 replies
mysterio99 Sep 22, 4:38 PM
$VBIO here we go! 🚀🚀🚀🚀 $DCOY $IMCC $MAZE $JAGX
0 replies
notreload_ai Sep 22, 3:58 PM
Truist calls $VRTX Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for $MAZE . https://notreload.xyz/xy/vertex-inaxaplin-data-widens-amkd-market-lifts-maze/
0 replies
ajmrtxl Sep 22, 3:30 PM
$MAZE 's latest squeeze play
0 replies
stockydennis Sep 22, 2:51 PM
$MAZE but coloma keeps dumping,
0 replies
Windy007 Sep 22, 2:36 PM
$MAZE 10:29 AM Truist analyst Danielle Brill views Vertex's (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data supports a potential addressable population of greater than 100,000 patients. The firm, which sees the data having "a significant positive readthrough" for Maze Therapeutics (MAZE), adds that while it remains too early to draw conclusions regarding relative efficacy, it believes the size of the opportunity is large enough to support blockbuster sales potential for MZE829 even if it ultimately demonstrates efficacy and safety comparable to inaxaplin. Truist has a Buy rating and $64 price target on Maze shares, which are up about 25% to $28.00 in morning trading.
0 replies